Can systemic corticosteroids be used safely in a patient who has both psoriasis and rheumatoid arthritis?

Can Systemic Steroids Be Given in Psoriasis with Rheumatoid Arthritis?

Yes, systemic corticosteroids may be used with caution at the lowest effective dose for short-term control in patients with both psoriasis and rheumatoid arthritis, but they should not be a long-term solution and require careful monitoring for psoriasis flares.

Key Recommendation from Guidelines

The 2020 EULAR recommendations for psoriatic arthritis explicitly state that "systemic glucocorticoids may be used with caution at the lowest effective dose" 1. This guidance applies to patients with psoriatic arthritis (which shares the psoriasis component with your scenario), and the principles extend to patients with psoriasis and rheumatoid arthritis.

Clinical Approach

When Systemic Steroids Can Be Considered:

• Short-term bridging therapy while initiating or switching DMARDs
• Acute flares of joint disease requiring rapid control
• Lowest effective dose: typically ≤7.5 mg/day prednisone equivalent 2
• Limited duration: avoid chronic use (>6 months) 3

Critical Cautions Specific to Psoriasis:

The traditional fear of systemic steroids in psoriasis centers on rebound flares upon withdrawal 2. However, the evidence is nuanced:

• The 2012 EULAR guidelines note that literature supporting psoriasis flares with steroids is limited to case reports, not robust clinical data 2
• Registry data show systemic steroids are actually widely used in psoriatic arthritis (up to 30% of patients) at low doses 2
• Greater caution is warranted in patients with severe/extensive skin involvement and those not taking concomitant DMARDs 2

Practical Algorithm:

1. Assess psoriasis severity: Extensive skin involvement = higher risk of rebound flare
2. Ensure DMARD coverage: Methotrexate or other DMARDs should be initiated/continued to provide disease control and potentially reduce flare risk 2
3. Use lowest effective dose: Keep at ≤7.5 mg/day prednisone equivalent
4. Plan for short duration: Use as bridging therapy only (weeks, not months)
5. Taper carefully: Slow taper while monitoring skin closely for rebound 2

Preferred Long-Term Strategy

The goal should be to avoid chronic systemic steroids entirely 1, 4. Instead:

• First-line: Methotrexate is preferred as it treats both joint disease and skin involvement 1
• If inadequate response: Advance to biologics (TNF inhibitors, IL-17 inhibitors, or IL-12/23 inhibitors) 1
• Local steroid injections are preferred for oligoarticular disease 1

Important Pitfalls to Avoid:

• Do not use systemic steroids for axial disease (if present) 1
• Avoid abrupt discontinuation - taper slowly to minimize rebound psoriasis 2
• Do not rely on steroids as monotherapy - always combine with or transition to DMARDs 2
• Monitor for long-term toxicity: cardiovascular disease, metabolic syndrome, infections 3, 5

COVID-19 Era Consideration:

The 2020 National Psoriasis Foundation guidance specifically warns that chronic systemic corticosteroids should be avoided if possible and notes that chronic use at the time of SARS-CoV-2 infection may be associated with worse COVID-19 outcomes 4. This reinforces the principle of lowest dose, shortest duration.

Bottom Line:

Systemic steroids are not contraindicated but should be a temporary measure only, used at low doses with concurrent DMARD therapy, particularly in patients without extensive skin disease. The treatment paradigm should rapidly transition to steroid-sparing agents like methotrexate or biologics to achieve long-term disease control while minimizing both steroid toxicity and psoriasis flare risk.